Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma.
CONCLUSIONS: At current costs, cabozantinib is not cost-effective for second-line therapy of HCC in the United States.
PMID: 31200357 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver Cancer | Oral Cancer | Study | USA Health